These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24467966)

  • 1. mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma.
    Utomo WK; Narayanan V; Biermann K; van Eijck CH; Bruno MJ; Peppelenbosch MP; Braat H
    Cancer Lett; 2014 May; 346(2):309-17. PubMed ID: 24467966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
    Babiker HM; Karass M; Recio-Boiles A; Chandana SR; McBride A; Mahadevan D
    Expert Opin Investig Drugs; 2019 Jul; 28(7):583-592. PubMed ID: 31215251
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma.
    Ding L; Han L; Li Y; Zhao J; He P; Zhang W
    Neoplasia; 2014 Nov; 16(11):909-17. PubMed ID: 25425965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
    Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
    Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu?
    Rhim AD
    Cancer Biol Ther; 2009 Oct; 8(20):1902-3. PubMed ID: 19783905
    [No Abstract]   [Full Text] [Related]  

  • 8. A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation.
    Papageorgiou A; Avruch J
    Methods Mol Biol; 2012; 821():187-214. PubMed ID: 22125066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
    Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
    Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
    Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
    Kouvaraki MA; Liakou C; Paraschi A; Dimas K; Patsouris E; Tseleni-Balafouta S; Rassidakis GZ; Moraitis D
    Surgery; 2011 Dec; 150(6):1258-65. PubMed ID: 22136849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
    Zheng J; Zou X; Yao J
    Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes.
    Tasaka T; Akiyoshi T; Yamaguchi K; Tanaka M; Onishi H; Katano M
    Anticancer Res; 2010 Dec; 30(12):4999-5010. PubMed ID: 21187481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
    Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
    Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J; Xue L; Hao H; Han Y; Yang J; Luo J
    Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.